Augurex to Present Two Posters at ADLM 2024 in Chicago
Vancouver, Canada – July 26, 2024 – Augurex Life Sciences Corp. is pleased to announce that it will be presenting two posters at the upcoming Association for Diagnostic & Laboratory Medicine (ADLM 2024) in Chicago. The event will be held from July 28 to August 1, 2024, and it provides an unparalleled opportunity to share the latest advancements in clinical chemistry and laboratory medicine.
The details of Augurex’s poster presentations are as follows:
A-346. Evaluating 14-3-3η Detection in Finger Prick Blood Using Lateral Flow Technology: Advancing Clinical Laboratory Diagnostics
- Authors: N. Sidhu, V. Stojanovic, A. Marotta.
- Date & Time: July 30, 2024, 9:30 AM – 5:00 PM. Attended 1:30 PM – 2:30 PM.
- Overview: This study explores the detection of the 14-3-3η protein in finger prick blood samples using lateral flow technology. The research aims to advance clinical laboratory diagnostics by offering a rapid and reliable method for the early detection of inflammatory polyarthritis and other autoimmune rheumatologic disorders, potentially improving patient outcomes through earlier intervention.
- View full abstract: https://www.abstractsonline.com/pp8/#!/20594/presentation/302
B-065. Comparative Analysis of 14-3-3η Autoantibody Assays on Luminex Platform for Diagnosing Axial Spondyloarthritis
- Authors: N. Sidhu, W. P. Maksymowych, S. Wichuk, A. Marotta
- Date & Time: July 31, 2024, 9:30 AM – 5:00 PM. Attended 1:30 PM – 2:30 PM.
- Overview: This study presents a comparative analysis of 14-3-3η autoantibody (AAb) assay conducted on the Luminex platform, focusing on its efficacy in diagnosing axial spondyloarthritis (AS). Notably, combining 14-3-3η AAbs and C-reactive protein levels identified 90% of AS patients, underscoring the potential of these biomarkers as powerful and complementary diagnostic tools for enhanced early detection of AS to improve patient outcomes.
- View full abstract: https://www.abstractsonline.com/pp8/#!/20594/presentation/301
These poster presentations underscore Augurex’s commitment to advancing diagnostic solutions and improving patient outcomes in the field of autoimmune diseases.
About Augurex
Augurex is a commercial stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world. Augurex’ lead diagnostic test, available as 14-3-3η in the U.S., and as JOINTstat® in Canada and Europe, is an important tool in the diagnosis and management of inflammatory diseases, including rheumatoid arthritis, lupus and other autoimmune conditions. SPINEstat® expands Augurex’ biomarker-informed diagnostic autoimmune portfolio into Ankylosing Spondylitis, an autoimmune disease often misdiagnosed as low back pain, and which if untreated can lead to impaired spinal mobility and fusion of the vertebrae. Learn more about Augurex at www.augurex.com and follow us on LinkedIn and X.
Comments are closed.